AU Patent

AU2008273002C1 — Pyrimidine derivatives useful as Raf kinase inhibitors

Assigned to Viracta Therapeutics Inc · Expires 2017-07-20 · 9y expired

What this patent protects

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

USPTO Abstract

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Drugs covered by this patent

Patent Metadata

Patent number
AU2008273002C1
Jurisdiction
AU
Classification
—
Expires
2017-07-20
Drug substance claim
No
Drug product claim
No
Assignee
Viracta Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.